EFFECTS OF ADDING NICORANDIL TO STANDARD THERAPY IN PATIENTS WITH ISCHEMIC HEART FAILURE
Abstract:
Introduction. Nicorandil, a vasodilator with strong coronary and peripheral vascular activity is current used as an antianginal agent, but its effect in heart failure (HF) patients has not been fully established. Therefore, we examined impact of nicorandil in outcomes of ischemic HF patients. Materials and methods. HF patients with ischemic etiology were prospectively registered and divided into 2 groups based on oral administration of nicorandil: nicorandil group (n = 6) and non-nicorandil group (n=6). Patients were randomly assigned to be treated with or without oral nicorandil, 10 mg twice daily for 5 days. BNP values were measured at admission and at 5th day. Patients undergo ecocardiography exam and 6 minutes walk test. Results: Echocardiographic measurements showed no statistical relevant differences between groups. The mean distance at the 6minute walk test has higher in the nicorandil group (396 meters) versus non-nicorandil group (320 meters) and BNP levels after 5 days were decreased significant in the nicorandil group. Conclusion: Nicorandil is potentially effective for treatment in patients with ischemic heart failure.
full text article in English (.EN) |